"Corner Therapeutics Launches $54M Initiative to Hyperactivate Immune System's 'Brain'"
Corner Therapeutics has secured $54 million in Series A funding to develop new immunotherapies for cancer and infectious diseases. The startup, led by Steve Altschuler, aims to hyperactivate the immune system's response to these conditions and bring innovative treatments to the clinic. The funding was led by Ziff Capital Partners, with contributions from Cockrell Interests, Tanis Ventures, and Sandia Holdings.